Australia markets close in 4 hours 32 minutes

Zealand Pharma A/S (ZEAL)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
21.36+0.07 (+0.33%)
At close: 11:36AM EST

Zealand Pharma A/S

Sydmarken 11
Copenhagen 2860
45 88 77 36 00

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 346

Key executives

NameTitlePayExercisedYear born
Dr. Emmanuel Dulac Pharm.D., PharmD, Ph.D., MBACEO & Pres1.88MN/A1969
Mr. Matthew Donald DallasSr. VP & CFO854.64kN/A1975
Ms. Hanne Heidenheim BakSr. Project Director, R&D Operations Mang. and Employee Representative Director20.05kN/A1953
Mr. Adam Sinding Steensberg M.D.Exec. VP of R&D and Chief Medical Officer1.11MN/A1974
Mr. Ivan Mourits MøllerSr. VP of Technical Devel. & OperationsN/AN/A1972
Ms. Rie Schultz HansenVP of Discovery & InnovationN/AN/AN/A
Lani Pollworth MorvanInvestor Relations & Communications OfficerN/AN/AN/A
Mr. Mads KronborgHead of Investor Relations & CommunicationN/AN/AN/A
Søren Vitfell KellerHead of Legal AffairsN/AN/AN/A
Ms. Christina Sonnenborg BredalVP and Head of People & OrganizationN/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin, Lyxumia, Soliqua 100/33, and Suliqua. Its product pipeline includes Dasiglucagon single use syringe or autoinjector that has completed Phase III clinical trials for the treatment of severe hypoglycemia; Dasiglucagon dual-hormone artificial pancreas has completed Phase II clinical trials for automated diabetes management; Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism and in Phase II clinical trials for post bariatric surgery hypoglycemia. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion; and Beta Bionics, Inc. The company was founded in 1997 and is headquartered in Copenhagen, Denmark.

Corporate governance

Zealand Pharma A/S’s ISS governance QualityScore as of 26 September 2021 is 1. The pillar scores are Audit: 3; Board: 2; Shareholder rights: 1; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.